Update on stents: Recent studies on the TAXUS® stent system in small vessels

Shuzou Tanimoto, Joost Daemen, Patrick W SerruysThoraxcenter, Erasmus Medical Center, Rotterdam, The NetherlandsAbstract: Small vessel size (<3 mm) has been identified as an independent predictive factor of restenosis after percutaneous coronary intervention when using bare metal stents (BMS)...

Full description

Bibliographic Details
Main Authors: Shuzou Tanimoto, Joost Daemen, Patrick W Serruys
Format: Article
Language:English
Published: Dove Medical Press 2007-09-01
Series:Vascular Health and Risk Management
Online Access:https://www.dovepress.com/update-on-stents-recent-studies-on-the-taxussupregsup-stent-system-in--peer-reviewed-article-VHRM
_version_ 1818875298649735168
author Shuzou Tanimoto
Joost Daemen
Patrick W Serruys
author_facet Shuzou Tanimoto
Joost Daemen
Patrick W Serruys
author_sort Shuzou Tanimoto
collection DOAJ
description Shuzou Tanimoto, Joost Daemen, Patrick W SerruysThoraxcenter, Erasmus Medical Center, Rotterdam, The NetherlandsAbstract: Small vessel size (<3 mm) has been identified as an independent predictive factor of restenosis after percutaneous coronary intervention when using bare metal stents (BMS). It remains controversial whether BMS placement in small vessels has an advantage over balloon angioplasty in terms of angiographic and clinical outcomes. The advent of drug eluting stents (DES), either paclitaxel-eluting stents (PES) or sirolimus-eluting stents (SES), has strongly impacted interventional cardiology by significantly reducing restenosis and the need for repeat revascularization. Therefore, it was also expected that DES could substantially reduce restenosis in smaller vessels. However, even in the DES era, small vessel size remains an independent predictor of angiographic and clinical restenosis. To date, only a few studies systematically investigate the clinical effect of DES placement in small vessels. In addition, some potential issues with the use of DES have been raised, such as late stent thrombosis and late restenosis. In order to (i) establish the superiority of DES over BMS; (ii) verify the efficacy and safety of DES; and (iii) critically assess the superiority of one DES over the other in patients with small coronary arteries, further multicenter, randomized clinical trials with larger sample size are warranted.Keywords: paclitaxel, stent, coronary artery disease, restenosis
first_indexed 2024-12-19T13:24:17Z
format Article
id doaj.art-fa1adaec260a4f46b61a162c88c653c9
institution Directory Open Access Journal
issn 1178-2048
language English
last_indexed 2024-12-19T13:24:17Z
publishDate 2007-09-01
publisher Dove Medical Press
record_format Article
series Vascular Health and Risk Management
spelling doaj.art-fa1adaec260a4f46b61a162c88c653c92022-12-21T20:19:37ZengDove Medical PressVascular Health and Risk Management1178-20482007-09-01Volume 34814901501Update on stents: Recent studies on the TAXUS® stent system in small vesselsShuzou TanimotoJoost DaemenPatrick W SerruysShuzou Tanimoto, Joost Daemen, Patrick W SerruysThoraxcenter, Erasmus Medical Center, Rotterdam, The NetherlandsAbstract: Small vessel size (<3 mm) has been identified as an independent predictive factor of restenosis after percutaneous coronary intervention when using bare metal stents (BMS). It remains controversial whether BMS placement in small vessels has an advantage over balloon angioplasty in terms of angiographic and clinical outcomes. The advent of drug eluting stents (DES), either paclitaxel-eluting stents (PES) or sirolimus-eluting stents (SES), has strongly impacted interventional cardiology by significantly reducing restenosis and the need for repeat revascularization. Therefore, it was also expected that DES could substantially reduce restenosis in smaller vessels. However, even in the DES era, small vessel size remains an independent predictor of angiographic and clinical restenosis. To date, only a few studies systematically investigate the clinical effect of DES placement in small vessels. In addition, some potential issues with the use of DES have been raised, such as late stent thrombosis and late restenosis. In order to (i) establish the superiority of DES over BMS; (ii) verify the efficacy and safety of DES; and (iii) critically assess the superiority of one DES over the other in patients with small coronary arteries, further multicenter, randomized clinical trials with larger sample size are warranted.Keywords: paclitaxel, stent, coronary artery disease, restenosishttps://www.dovepress.com/update-on-stents-recent-studies-on-the-taxussupregsup-stent-system-in--peer-reviewed-article-VHRM
spellingShingle Shuzou Tanimoto
Joost Daemen
Patrick W Serruys
Update on stents: Recent studies on the TAXUS® stent system in small vessels
Vascular Health and Risk Management
title Update on stents: Recent studies on the TAXUS® stent system in small vessels
title_full Update on stents: Recent studies on the TAXUS® stent system in small vessels
title_fullStr Update on stents: Recent studies on the TAXUS® stent system in small vessels
title_full_unstemmed Update on stents: Recent studies on the TAXUS® stent system in small vessels
title_short Update on stents: Recent studies on the TAXUS® stent system in small vessels
title_sort update on stents recent studies on the taxus reg stent system in small vessels
url https://www.dovepress.com/update-on-stents-recent-studies-on-the-taxussupregsup-stent-system-in--peer-reviewed-article-VHRM
work_keys_str_mv AT shuzoutanimoto updateonstentsrecentstudiesonthetaxusregstentsysteminsmallvessels
AT joostdaemen updateonstentsrecentstudiesonthetaxusregstentsysteminsmallvessels
AT patrickwserruys updateonstentsrecentstudiesonthetaxusregstentsysteminsmallvessels